glp-1 safety for weight loss Agonists Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH How GLP-1 Medications Boost Weight

Any use outside approved indications would be considered off-label prescribing, which requires careful clinical justification and informed patient consent

A new trial has reported that the GLP-1 receptor agonist semaglutide reduces risk of cardiovascular events in patients with obesity but thats not the question we ought to be asking

The company has discontinued glyphosate-based Roundup for residential use and is pursuing regulatory approval for a new herbicide across major global markets

One of the primary actions of BPC-157 is strengthening the gut barrier

Do I need extra protein with GLP-1

A recent systematic review (Vasireddi et al., Am J Sports Med 2025) confirms the potential in sports medicine